CSL Limited (OTCMKTS:CSLLY) Sees Significant Growth in Short Interest

CSL Limited (OTCMKTS:CSLLY) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totalling 4,200 shares, an increase of 133.3% from the August 31st total of 1,800 shares. Based on an average trading volume of 45,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Macquarie upgraded shares of CSL to a “strong-buy” rating in a research report on Tuesday, August 13th.

CSL Stock Performance

Shares of CSLLY stock traded down $1.55 during trading hours on Friday, hitting $99.07. 16,508 shares of the company’s stock were exchanged, compared to its average volume of 30,326. The company has a current ratio of 2.18, a quick ratio of 0.97 and a debt-to-equity ratio of 0.58. CSL has a 12-month low of $71.51 and a 12-month high of $109.00. The business’s 50 day simple moving average is $101.59 and its 200-day simple moving average is $96.86.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.